Rajneesh Nath

Chief, Stem Cell Transplatation & Cellular Therapy
Banner MD Anderson Cancer Center,

[Rajneesh Nath @NeeshR0]

@KrishPatelMD @RahulBanerjeeMD @NitinJainMD @ASkarbnik @mshadman @DrMDavids @DanilovLab @DebbieMStephens @RyanWJacobs @LoriLeslieMD @AdamKittai @BrianHill_MDPhD @andrewlipskymd @calliecoombsmd @dbranderMD Either choice is delaying the inevitable. We need to throw allo ScT in the midst too. Mortality is in the 10-20 range. And a good number off all therapy and cured.

[Rajneesh Nath @NeeshR0]

@TalhaBadarMD Excellent summary of P53 mutated AML.
Any data/comments on donor source for allo SCT- specifically cord blood?

[Rajneesh Nath @NeeshR0]

@BijoyTelivala @OncBrothers @RenoHemonc @AaronGoodman33 @Eddie_Cliff @Dr_AmerZeidan @beatalleukemia Sonora Quest in Tempe Arizona will result NGS in 72 hours if they are told that it is a newly diagnosed AML.

[Rajneesh Nath @NeeshR0]

@LoriMuffly @sghmd @drkomanduri @DrMonzrAlMalki @ASTCT @Chrislemieux90 @DrMiguelPerales Additional possibility is prolonged HMA/ Ven if the patient goes into an early CR.

Limited data with haplo DLI but certainly a possibility. Be prepared for higher incidence of acute gvhd

[Rajneesh Nath @NeeshR0]

@LoriMuffly @sghmd @drkomanduri @DrMonzrAlMalki @ASTCT @Chrislemieux90 @DrMiguelPerales While it is tempting to change the donor, I am not sure that we have data to support it. EBMT has shown similar outcomes of same versus different donor
https://t.co/i8Oh1MdVTC
Without being prescriptive, I would go with the the highest intensity that you think you can give

[Rajneesh Nath @NeeshR0]

@LoriMuffly @DrMiguelPerales @sghmd @BldCancerDoc @drkomanduri @AmyDeZern @DrMonzrAlMalki @CatherineLeeMD @arpitapgandhi @khera_nandita @hamiltkyb @hemedoc @ASTCT Thiotepa 2.5- 5 mg/kg, fludarabine and Mel 100

[Rajneesh Nath @NeeshR0]

@dgomezalmaguer Clearly, there is a role for allo in a young patient with good PS , high risk disease and with good response ( CR)to frontline therapy.
What was your conditioning? TBI?
What was the gvhd prophylaxis? PTCy?

[Rajneesh Nath @NeeshR0]

@MarkFaberDO @BannerHealth @MattUlricksonMD @RoswellLeukemia Welcome aboard Mark

[Rajneesh Nath @NeeshR0]

@GomezDLeonMD Your favorite RIC with PTCy.
TKI for two years post SCT

[Rajneesh Nath @NeeshR0]

@LugoMd @Anand_88_Patel @Daver_Leukemia @NicholasShortMD @MartinTallman @LuskinMarlise @DrHKantarjian @AaronGoodman33 @TalhaBadarMD Favorite ALL regimen at your center. If MRD neg blin x 4 bard on the LBA. Not sure blin needs to follow on E1910

[Rajneesh Nath @NeeshR0]

@GvHD_Meade @GomezDLeonMD Other the other hand there is no data suggesting that is not useful either.

[Rajneesh Nath @NeeshR0]

@BMDACCstemcell Our talented crew who made #SCTsymposiumBMDACC possible.
A big shoutout to our APPs, nurses, physicians, pharmacists, CryoLab, data management group, Quality team, MAs, AAs and Research team!!!

[Rajneesh Nath @NeeshR0]

@khera_nandita @ASTCT Congratulations Nandita

[Rajneesh Nath @NeeshR0]

@Rfonsi1 Looks like the obituary is being written when the person ( SCT for lymphoma) is still alive. SCT will still be there. Don’t forget the cytopenias (30%) and prolonged B lymphopenia ( and consequent low IGG) . Allo SCT is still curative after progression from CAR-T

[Rajneesh Nath @NeeshR0]

@RocioCamachoMD If the patient continues to have detectable MRD at the end of consolidation , allo would be appropriate

[Rajneesh Nath @NeeshR0]

@bpiperdi Sorry to hear about your loss .

[Rajneesh Nath @NeeshR0]

https://t.co/Rdb3YgfHXA